LATEST UPDATES » Big Data, Bigger Disease Management and Current preparations to manage the Future Health of Singaporeans       » Big Data in Clinical Research Sector       » Professor Yuk-ling Yung receives Gerard P. Kuiper Prize       » AXA Assistance on Regenerative Medicine       » Singtel – Singapore Cancer Society Race against Cancer 2015       » Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death      
Daiichi Sankyo announces development of nucleic acid treatment for Duchenne muscular dystrophy utilizing proprietary technology
Daiichi Sankyo Co., Ltd. will establish a new company, Orphan Disease Treatment Institute Co., Ltd., with Innovation Network Corporation of Japan (INCJ) and Mitsubishi UFJ Capital Co., Ltd. (MUC). Daiichi Sankyo will collaborate with the new company to undertake development of a treatment for Duchenne muscular dystrophy (DMD) with the active ingredient ENA® oligonucleotide*, a modified nucleic acid made using proprietary technology owned by Daiichi Sankyo.

ENA® is an ethylene-bridged nucleic acid in which ethylene is bridged at the furanose sugar ring at 2’-O and 4’-C ends. Short-chain nucleic acids and ENA® oligonucleotides found in ENA® demonstrate high binding force with complementary DNA and RNA as well as superior thermal stability and nuclease resistance.

INCJ will underwrite third party allocation of new shares for the new company with a maximum investment of ¥1.65 billion. The new company will also issue new shares by third party allocation for a fund managed by MUC. Daiichi Sankyo will invest in the new company and mainly conduct development with the goal of achieving proof of concept (POC) for clinical drug development.

DMD is known as a disease that affects one in 3,500 new-born males regardless of ethnicity. The onset of the disease occurs between the age of two and five, at first slightly affecting the ability to be self-reliant. DMD is associated with muscular atrophy which progresses with age, causing various impairments to mobility and finally resulting in death for many in their 20s and 30s. It is an extremely serious and rare hereditary X-linked recessive genetic disorder. It is known that DMD occurs because muscle cells do not produce dystrophin, but there is no fundamental or effective therapy available.

In 2006, professor Masafumi Matsuo (Kobe Gakuin University Department of Medical Rehabilitation) and designated professor Yasuhiro Takeshima (Kobe University Graduate School of Medicine Department of Pediatrics) were the first in the world to demonstrate the effectiveness of anti-sense oligonucleotides to restore dystrophin expression in DMD sufferers through the mechanism known as exon skipping (Pediatr. Res., 59:690-694, 2006). Daiichi Sankyo and Orphan Disease Treatment Institute will jointly conduct clinical and non-clinical studies with the cooperation and support of these two professors with the aim of achieving POC. 

Click here for the complete issue.

news Runners' High, Happy Feet — If you're Happy, and you know it 'Clap' your Feet
news Snapshot of Stem Cell Expression using Single-cell RNA Sequencing
news A Heroic Voyage — Sydney Brenner's Life in Science
news VeloX, A Minimally Invasive Prosthetic Heart Valve for treating Mitral Regurgitation
news Anti-CD25 monoclonal antibody (90Y-daclizumab) a favorable target towards systemic radio-immunotherapy in Hodgkin's Lymphoma

Credits to Sony Computer Entertainment and click here for behind the scenes.

APBN Editorial Calendar 2015
Trends and Predictions for 2015 Robotics in Healthcare Nutrition Universal Health Coverage
Start-Up Biotech Companies Preventative and Translational Medicine Biofuels ASEAN Economic Community and Asia's Life Sciences Industry
Big Data: Healthcare and Drug Development Antibody Engineering in Japan Christmas Edition
APBN Editorial Calendar 2016
Korea's Biotechnology Industry Nutrition and Allergies: Are we, Too Clean? Medical Devices and Technology: Innovation that leaves an Inspiration Tobacco Smoking: The 'Real' Cost of One Cigarette
Life-Saving Opportunities: A Guide to Regenerative Medicine Occupational Health Water Technology Olympics: Evolution of Sports
Respiratory: Seasonal flu viruses
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy